Christine Brown

List of Publications by Year
in descending order

108 papers	10,143 citations	38742 50 h-index	37204 96 g-index
114 all docs	114 docs citations	114 times ranked	11183 citing authors

#	Article	IF	Citations
1	Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma. NeuroMolecular Medicine, 2022, 24, 35-40.	3.4	6
2	Off-the-shelf, steroid-resistant, IL13RÎ±2-specific CAR T cells for treatment of glioblastoma. Neuro-Oncology, 2022, 24, 1318-1330.	1.2	32
3	Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy. PLoS Computational Biology, 2022, 18, e1009504.	3.2	8
4	Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models. International Journal of Molecular Sciences, 2022, 23, 3154.	4.1	15
5	3D-organoid culture supports differentiation of human CAR+ iPSCs into highly functional CAR TÂcells. Cell Stem Cell, 2022, 29, 515-527.e8.	11.1	57
6	Loss of SIRT1 inhibits hematopoietic stem cell aging and age-dependent mixed phenotype acute leukemia. Communications Biology, 2022, 5, 396.	4.4	7
7	Spatial organization of heterogeneous immunotherapy target antigen expression in high-grade glioma. Neoplasia, 2022, 30, 100801.	5.3	2
8	The future of cancer immunotherapy for brain tumors: a collaborative workshop. Journal of Translational Medicine, 2022, 20, .	4.4	7
9	Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression. Nature Communications, 2022, 13, .	12.8	29
10	Abstract CT541A: Oncolytic viral reshaping of the tumor microenvironment to promote CAR T cell therapy for glioblastoma. Cancer Research, 2022, 82, CT541A-CT541A.	0.9	1
11	Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells. , 2022, 10, e003752.		4
12	A metabolic switch to memory CAR T cells: Implications for cancer treatment. Cancer Letters, 2021, 500, 107-118.	7.2	21
13	CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies. Cancer Discovery, 2021, 11, 1192-1211.	9.4	78
14	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. Cancer Immunology Research, 2021, 9, 75-88.	3.4	24
15	Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine. OncoImmunology, 2021, 10, 1899469.	4.6	28
16	Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment. Neurosurgery, 2021, 88, 1056-1064.	1.1	14
17	Abstract PO083: Treatment of CEA-positive solid tumors with anti-CEA chimeric antigen receptor T-cells in CEA transgenic mice. Cancer Immunology Research, 2021, 9, PO083-PO083.	3.4	2
18	Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy. Frontiers in Immunology, 2021, 12, 635173.	4.8	41

#	Article	IF	Citations
19	IFNÎ³ Is Critical for CAR T Cellâ€"Mediated Myeloid Activation and Induction of Endogenous Immunity. Cancer Discovery, 2021, 11, 2248-2265.	9.4	86
20	Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. , 2021, 9, e002181.		42
21	Mitochondria as Playmakers of CAR T-cell Fate and Longevity. Cancer Immunology Research, 2021, 9, 856-861.	3.4	12
22	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Advances, 2021, 5, 4059-4063.	5.2	62
23	Unique challenges for glioblastoma immunotherapyâ€"discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro-Oncology, 2021, 23, 356-375.	1.2	59
24	Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers. Drug Delivery and Translational Research, 2021, 11, 2448-2467.	5.8	8
25	Vitamin C, From Supplement to Treatment: A Re-Emerging Adjunct for Cancer Immunotherapy?. Frontiers in Immunology, 2021, 12, 765906.	4.8	12
26	EXTH-10. EXPLORATION OF A NOVEL TOXIN-INCORPORATING CAR T CELL: HOW DOES CHLOROTOXIN RECOGNIZE GLIOBLASTOMA CELLS?. Neuro-Oncology, 2021, 23, vi165-vi165.	1.2	0
27	CTIM-29. CLINICAL EVALUATION OF CHLOROTOXIN-DIRECTED CAR T CELLS FOR PATIENTS WITH RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2021, 23, vi57-vi57.	1.2	0
28	Repeatability of tumor perfusion kinetics from dynamic contrast-enhanced MRI in glioblastoma. Neuro-Oncology Advances, 2021, 3, vdab174.	0.7	3
29	Integrin Î±6 signaling induces STAT3-TET3-mediated hydroxymethylation of genes critical for maintenance of glioma stem cells. Oncogene, 2020, 39, 2156-2169.	5.9	23
30	Systemic Antiâ€"PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid. JAMA Oncology, 2020, 6, 1947.	7.1	28
31	Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nature Communications, 2020, 11, 2283.	12.8	130
32	Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Science Translational Medicine, 2020, 12, .	12.4	150
33	Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. Journal of the Royal Society Interface, 2020, 17, 20190734.	3.4	58
34	Chimeric antigen receptor signaling: Functional consequences and design implications. Science Advances, 2020, 6, eaaz3223.	10.3	81
35	CAR T cells for brain tumors: Lessons learned and road ahead. Immunological Reviews, 2019, 290, 60-84.	6.0	151
36	IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunology Research, 2019, 7, 759-772.	3.4	235

#	Article	IF	Citations
37	In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function. Journal of Visualized Experiments, 2019, , .	0.3	19
38	CAR T cell therapy: inroads to response and resistance. Nature Reviews Immunology, 2019, 19, 73-74.	22.7	148
39	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. Blood, 2019, 134, 4075-4075.	1.4	10
40	Regional Delivery of Chimeric Antigen Receptorâ€"Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clinical Cancer Research, 2018, 24, 95-105.	7.0	220
41	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptorâ€"Redirected T Cells Against Multiple Myeloma. Clinical Cancer Research, 2018, 24, 106-119.	7.0	136
42	Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. OncoImmunology, 2018, 7, e1380764.	4.6	111
43	Optimization of IL13RÎ±2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Molecular Therapy, 2018, 26, 31-44.	8.2	217
44	Chimeric Antigen Receptor T-Cell Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1092-1106.	4.9	15
45	Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight, 2018, 3, .	5.0	150
46	PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with ⁸⁹Zr-Oxine. Journal of Nuclear Medicine, 2018, 59, 1531-1537.	5.0	111
47	CD19-CAR Therapy Using Naive/Memory or Central Memory T Cells Integrated into the Autologous Stem Cell Transplant Regimen for Patients with B-NHL. Blood, 2018, 132, 610-610.	1.4	9
48	Adult Patients with ALL Treated with CD62L+ T NaÃ¯ve/Memory-Enriched T Cells Expressing a CD19-CAR Mediate Potent Antitumor Activity with a Low Toxicity Profile. Blood, 2018, 132, 4016-4016.	1.4	11
49	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Science Translational Medicine, 2017, 9, .	12.4	263
50	Human Neural Stem Cell Biodistribution and Predicted Tumor Coverage by a Diffusible Therapeutic in a Mouse Glioma Model. Stem Cells Translational Medicine, 2017, 6, 1522-1532.	3.3	24
51	Chimeric antigen receptor T-cell therapy for glioblastoma. Translational Research, 2017, 187, 93-102.	5.0	27
52	Targeting Alpha-Fetoprotein (AFP)â€"MHC Complex with CAR T-Cell Therapy for Liver Cancer. Clinical Cancer Research, 2017, 23, 478-488.	7.0	158
53	Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications. Frontiers in Immunology, 2017, 8, 1850.	4.8	161
54	IMMU-08. THERAPEUTIC POTENTIAL OF CHLOROTOXIN-REDIRECTED CAR-T CELLS AGAINST HETEROGENEOUS GLIOBLASTOMAS. Neuro-Oncology, 2017, 19, vi114-vi114.	1.2	2

#	Article	IF	Citations
55	L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice. PLoS ONE, 2016, 11, e0146885.	2.5	34
56	Next frontiers in CAR T-cell therapy. Molecular Therapy - Oncolytics, 2016, 3, 16028.	4.4	20
57	Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. New England Journal of Medicine, 2016, 375, 2561-2569.	27.0	1,326
58	Phase 1 studies of central memoryâ€"derived CD19 CAR Tâ€"cell therapy following autologous HSCT in patients with B-cell NHL. Blood, 2016, 127, 2980-2990.	1.4	264
59	Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis. Nature Communications, 2016, 7, 10637.	12.8	67
60	Comparison of naÃ¯ve and central memory derived CD8⁺effector cell engraftment fitness and function following adoptive transfer. OncoImmunology, 2016, 5, e1072671.	4.6	25
61	New Therapeutic Approach for Central Nervous System Lymphoma By Intracerebroventricular Delivery of CD19CAR T Cells. Blood, 2016, 128, 2161-2161.	1.4	0
62	Smart CARs engineered for cancer immunotherapy. Current Opinion in Oncology, 2015, 27, 466-474.	2.4	63
63	Bioactivity and Safety of IL13RÎ±2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clinical Cancer Research, 2015, 21, 4062-4072.	7.0	573
64	CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical Cancer Research, 2015, 21, 2993-3002.	7.0	52
65	Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy. Molecular Therapy, 2015, 23, 757-768.	8.2	169
66	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. Blood, 2015, 126, 930-930.	1.4	2
67	Ex Vivo AKT Inhibition Promotes the Generation of Potent CD19CAR T Cells for Adoptive Immunotherapy. Blood, 2015, 126, 3086-3086.	1.4	0
68	Diverse Solid Tumors Expressing a Restricted Epitope of L1-CAM Can Be Targeted by Chimeric Antigen Receptor Redirected T Lymphocytes. Journal of Immunotherapy, 2014, 37, 93-104.	2.4	50
69	Targeting JAK1/STAT3 Signaling Suppresses Tumor Progression and Metastasis in a Peritoneal Model of Human Ovarian Cancer. Molecular Cancer Therapeutics, 2014, 13, 3037-3048.	4.1	71
70	Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro-Oncology, 2014, 16, 1304-1312.	1.2	131
71	TLR9 Is Critical for Glioma Stem Cell Maintenance and Targeting. Cancer Research, 2014, 74, 5218-5228.	0.9	60
72	CS-1 Re-Directed Central Memory T Cell Therapy for Multiple Myeloma. Blood, 2014, 124, 1114-1114.	1.4	1

#	Article	IF	Citations
73	A Novel Berbamine Derivative Inhibits Cell Viability and Induces Apoptosis in Cancer Stem-Like Cells of Human Glioblastoma, via Up-Regulation of miRNA-4284 and JNK/AP-1 Signaling. PLoS ONE, 2014, 9, e94443.	2.5	57
74	Cytokine Induction of VCAM-1 but Not IL13RÎ±2 on Glioma Cells: A Tale of Two Antibodies. PLoS ONE, 2014, 9, e95123.	2.5	1
75	Neural Stem Cellâ€"Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies. Science Translational Medicine, 2013, 5, 184ra59.	12.4	194
76	Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase. Gene Therapy, 2013, 20, 853-860.	4.5	22
77	Chimeric Î³c cytokine receptors confer cytokine independent engraftment of human T lymphocytes. Molecular Immunology, 2013, 56, 1-11.	2.2	12
78	Neural Stem Cell-Mediated Delivery of Irinotecan-Activating Carboxylesterases to Glioma: Implications for Clinical Use. Stem Cells Translational Medicine, 2013, 2, 983-992.	3.3	58
79	Magnetic Resonance Imaging Tracking of Ferumoxytol-Labeled Human Neural Stem Cells: Studies Leading to Clinical Use. Stem Cells Translational Medicine, 2013, 2, 766-775.	3.3	88
80	Acute myeloid leukemia therapeutics. OncoImmunology, 2013, 2, e27214.	4.6	9
81	T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood, 2013, 122, 3138-3148.	1.4	322
82	Engineering Human T Cells for Resistance to Methotrexate and Mycophenolate Mofetil as an In Vivo Cell Selection Strategy. PLoS ONE, 2013, 8, e65519.	2.5	25
83	Glioma IL13RÎ±2 Is Associated with Mesenchymal Signature Gene Expression and Poor Patient Prognosis. PLoS ONE, 2013, 8, e77769.	2.5	126
84	Stem-like Tumor-Initiating Cells Isolated from IL13RÎ±2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakineâ€"Redirected T Cells. Clinical Cancer Research, 2012, 18, 2199-2209.	7.0	191
85	Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale. Journal of Immunotherapy, 2012, 35, 689-701.	2.4	128
86	Contact and Encirclement of Glioma Cells In Vitro Is an Intrinsic Behavior of a Clonal Human Neural Stem Cell Line. PLoS ONE, 2012, 7, e51859.	2.5	3
87	Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. Molecular Immunology, 2012, 51, 263-272.	2.2	158
88	CD123-Specific Chimeric Antigen Receptor Redirected T Cells Exhibit Potent Cytolytic Activity and Multiple Effector Functions Against Acute Myeloid Leukemia without Altering Normal Hematopoietic Colony Formation in Vitro. Blood, 2012, 120, 950-950.	1.4	1
89	Cytotoxic T Lymphocyte Trafficking and Survival in an Augmented Fibrin Matrix Carrier. PLoS ONE, 2012, 7, e34652.	2.5	6
90	Genome-Wide Profiling Identified a Set of miRNAs that Are Differentially Expressed in Glioblastoma Stem Cells and Normal Neural Stem Cells. PLoS ONE, 2012, 7, e36248.	2.5	100

#	Article	IF	Citations
91	Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy. Clinical Cancer Research, 2010, 16, 3399-3408.	7.0	63
92	Sorafenib Induces Growth Arrest and Apoptosis of Human Glioblastoma Cells through the Dephosphorylation of Signal Transducers and Activators of Transcription 3. Molecular Cancer Therapeutics, 2010, 9, 953-962.	4.1	110
93	Recognition and Killing of Brain Tumor Stem-Like Initiating Cells by CD8+ Cytolytic T Cells. Cancer Research, 2009, 69, 8886-8893.	0.9	118
94	Tumor-Derived Chemokine MCP-1/CCL2 Is Sufficient for Mediating Tumor Tropism of Adoptively Transferred T Cells. Journal of Immunology, 2007, 179, 3332-3341.	0.8	133
95	Medulloblastomas Expressing IL13RÎ±2 are Targets for IL13-zetakine+ Cytolytic T Cells. Journal of Pediatric Hematology/Oncology, 2007, 29, 669-677.	0.6	37
96	Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor. Cancer Gene Therapy, 2007, 14, 91-97.	4.6	52
97	Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. Journal of Immunological Methods, 2005, 297, 39-52.	1.4	57
98	A quantitative high-throughput chemotaxis assay using bioluminescent reporter cells. Journal of Immunological Methods, 2005, 302, 78-89.	1.4	12
99	T-cell genetic modification for re-directed tumor recognition. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 293-324.	0.5	15
100	Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells. Cancer Research, 2004, 64, 9160-9166.	0.9	342
101	Transcription Activator Interactions with Multiple SWI/SNF Subunits. Molecular and Cellular Biology, 2002, 22, 1615-1625.	2.3	160
102	Recruitment of HAT Complexes by Direct Activator Interactions with the ATM-Related Tra1 Subunit. Science, 2001, 292, 2333-2337.	12.6	334
103	The yeast SAS (something about silencing) protein complex contains a MYST-type putative acetyltransferase and functions with chromatin assembly factor ASF1. Genes and Development, 2001, 15, 3155-3168.	5.9	127
104	The many HATs of transcription coactivators. Trends in Biochemical Sciences, 2000, 25, 15-19.	7.5	325
105	Histone Acetyltransferase Complexes and Their Link to Transcription. Critical Reviews in Eukaryotic Gene Expression, 1999, 9, 231-243.	0.9	44
106	Poly(A) Tail Length Control in <i>Saccharomyces cerevisiae</i> Occurs by Message-Specific Deadenylation. Molecular and Cellular Biology, 1998, 18, 6548-6559.	2.3	197
107	Capped mRNA Degradation Intermediates Accumulate in the Yeast <i>spb8-2</i> Mutant. Molecular and Cellular Biology, 1998, 18, 5062-5072.	2.3	142
108	<i>PAN3</i> Encodes a Subunit of the Pab1p-Dependent Poly(A) Nuclease in <i>Saccharomyces cerevisiae</i>. Molecular and Cellular Biology, 1996, 16, 5744-5753.	2.3	149